-
Lenalidomide boosts CD1d-Vδ2 bispecific antibody-engaged Vγ9Vδ2-T cell effector functions via CD28, Notch signaling and IL-2 release
de Jong, M., Veth, M., Brachtlová, T., King, L. A., Saura-Esteller, J., Bechler, T. M., van Helden, P. M., Alhan, C., Lameris, R., de Gruijl, T. D. & van der Vliet, J. J., 28 Jun 2026, In: Journal for Immunotherapy of Cancer. 14, 6Research output: Contribution to Journal › Article › Academic › peer-review
-
A trophoblast glycoprotein specific 5T4-Vδ2 bispecific T cell engager recruits Vγ9Vδ2-T cells for tumor-selective cytotoxicity across solid malignancies
de Jong, M., Žiberna, R., Veth, M., Michielon, E., Myrda, J., Seidel, J., Akbarzadeh, M., van Helden, P. M., Vis, A. N., Derks, S., Lameris, R., de Gruijl, T. D. & van der Vliet, H. J., Jun 2026, In: Clinical immunology (Orlando, Fla.). 285, p. 110707 110707.Research output: Contribution to Journal › Article › Academic › peer-review
-
CD1d-specific single-domain antibodies for unconventional immunomodulation
Lameris, R., 3 May 2024, 249 p.Research output: PhD Thesis › PhD-Thesis - Research and graduation internal
- All publications
